Table 3. Lipinski & Veber rule.
| Compound | MW | iLogP | HBD (nOHNH) | HBA (nON) | nrotb | MR | TPSA | Lipinski #violations | Bio availability score |
| Lipinski* | ≤500 | ≤5 | ≤5 | ≤10 | ≤10 | - | - | ||
| Veber** | - | - | - | - | - | - | ≤ 140 | ||
| 1 | 357.83 | 3.46 | 1 | 4 | 7 | 100.1 | 58.37 | 0 | 0.55 |
| 2 | 474.98 | 4.31 | 1 | 4 | 8 | 143.37 | 61.61 | 0 | 0.55 |
| 3 | 397.9 | 3.97 | 1 | 4 | 7 | 116.32 | 58.37 | 0 | 0.55 |
| 4 | 519.98 | 3.32 | 1 | 6 | 9 | 152.19 | 107.43 | 1 | 0.55 |
| 5 | 543.87 | 4.42 | 1 | 4 | 8 | 153.39 | 61.61 | 2 | 0.17 |
| 6 | 533.02 | 4.93 | 1 | 7 | 9 | 153.68 | 80.07 | 1 | 0.55 |
| Azithromycin | 748.98 | 4.76 | 5 | 14 | 7 | 200.78 | 180.08 | 2 | 0.17 |
| Sulfanilamide | 172.2 | 0.61 | 2 | 3 | 1 | 41.84 | 94.56 | 0 | 0.55 |
| Sulfamethoxazole | 253.28 | 1.03 | 2 | 4 | 3 | 62.99 | 106.6 | 0 | 0.55 |